Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$84.18 USD

84.18
2,215,469

+1.14 (1.37%)

Updated Sep 27, 2024 01:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Glaxo (GSK) Earnings and Revenues Surpass Estimates in Q4

by Zacks Equity Research

Glaxo's (GSK) Q4 earnings and revenues beat estimates. In the event of Advair generic introduction in the U.S. market by mid 2018, Glaxo expects adjusted EPS to be flat to down at CER in 2018.

    FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up

    by Zacks Equity Research

    Gilead (GILD) gets a huge boost with the FDA's approval of its once-daily single tablet regimen (STR), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection.

      Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre

      by Zacks Equity Research

      Gilead (GILD) topped earnings and sales expectations in the fourth quarter but the guidance for 2018 was disappointing due to further weakness in the HCV franchise.

        The Zacks Analyst Blog Highlights: Walt Disney, Chipotle, Snap and Gilead Sciences

        by Zacks Equity Research

        The Zacks Analyst Blog Highlights: Walt Disney, Chipotle, Snap and Gilead Sciences

          Mark Vickery headshot

          New Quarterly Earnings Results for DIS, CMG, SNAP and More

          by Mark Vickery

          Will these companies reporting after the close -- DIS, CMG, SNAP and GILD -- catch a break in after-hours trading?

            Madeleine Johnson headshot

            Gilead (GILD) Posts Earnings Beat, Total Product Sales See YoY Decline

            by Madeleine Johnson

            Gilead Sciences (GILD) just released its fourth quarter fiscal 2017 financial results, posting earnings of $1.78 per share and revenues of $5.95 billion. Shares are down 2.4% to $78.50 in trading shortly after as a result.

              Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?

              by Zacks Equity Research

              Gilead's HCV franchise is under significant pressure due to increasing competition and the decline in franchise sales is expected to impact fourth-quarter results.

                Will Gilead (GILD) Disappoint Investors in Q4 Earnings?

                by Zacks Equity Research

                Biotech bigwig Gilead Sciences (GILD) Q4 results are expected to be adversely impacted by the decline in HCV market share.

                  Arpita Dutt headshot

                  Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi

                  by Arpita Dutt

                  While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.

                    Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid

                    by Zacks Equity Research

                    Celgene's (CELG) fourth-quarter results beat on both sales and earnings driven by solid growth in Revlimid and pick up in Otezla sales after a slowdown.

                      Bluebird Up on Buyout Speculation After Celgene/Juno Deal

                      by Zacks Equity Research

                      Bluebird Bio (BLUE) appears to be solid takeover target, with more and more companies expressing interest in the CAR-T space, especially after Celgene's acquisition of Juno Therapeutics.

                        Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion

                        by Zacks Equity Research

                        Celgene is set to acquire Juno Therapeutics for $87 per share or a total value of $9 billion to strengthen its position in the cellular immunotherapy space.

                          Gilead Collaborates with Pfizer for Yescarta Combo Study

                          by Zacks Equity Research

                          Kite, a Gilead Company (GILD), announced that it inked a clinical trial collaboration with Pfizer, for combination study.

                            The Zacks Analyst Blog Highlights: Apple, JPMorgan, AbbVie, Gilead and Simon Property Group

                            by Zacks Equity Research

                            The Zacks Analyst Blog Highlights: Apple, JPMorgan, AbbVie, Gilead and Simon Property Group

                              Juno Hits 52-Week High on Celgene's Rumored Buyout Interest

                              by Zacks Equity Research

                              Juno Therapeutics, Inc.'s (JUNO) shares hit a 52 week high on rumors of the company being acquired by Celgene Corporation.

                                Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA

                                by Zacks Equity Research

                                Novartis (NVS) gets a significant boost with the FDA approval of CAR-T Therapy Kymriah and the company is now looking to expand the therapy's label.

                                  Arpita Dutt headshot

                                  3 Top-Ranked Drug Stocks that are Broker Favorites

                                  by Arpita Dutt

                                  With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.

                                    Mark Vickery headshot

                                    Top Research Reports for Apple, JPMorgan & AbbVie

                                    by Mark Vickery

                                    Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), JPMorgan (JPM) and AbbVie (ABBV).

                                      Is Celgene (CELG) Looking to Take Over Juno Therapeutics?

                                      by Zacks Equity Research

                                      There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.

                                        Arpita Dutt headshot

                                        Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News

                                        by Arpita Dutt

                                        Is Celgene (CELG) in talks with Juno regarding a possible acquisition deal? This was the main news in the biotech sector this week.

                                          Can Biotech Keep Last Year's Momentum Alive in 2018?

                                          by Zacks Equity Research

                                          The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus

                                            by Arpita Dutt

                                            Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.

                                              Galapagos Reports Topline Data From Osteoarthritis Study

                                              by Zacks Equity Research

                                              Galapagos' (GLPG) osteoarthritis candidate, GLPG1972, reduces level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in an early stage study.

                                                Celgene to Acquire Impact Biomedicines to Boost Pipeline

                                                by Zacks Equity Research

                                                Celgene (CELG) announced that it will acquire Impact Biomedicines to bolster its oncology pipeline given the recent series of setbacks.

                                                  Arpita Dutt headshot

                                                  3 Biotech and Pharma Stocks with FDA Catalysts this January

                                                  by Arpita Dutt

                                                  2017 saw the FDA approving 46 novel drugs as well as path-breaking treatments like Novartis's (NVS) Kymriah and Gilead's Yescarta. Here is a look at three companies expecting a decision this January.